An open-lable, single-center, phase IA study to assess safety, tolerance, pharmacokinetics and efficacy of oral dosing icotinib hydrochloride tablets in various cancer patients,mainly in NSCLC.

Trial Profile

An open-lable, single-center, phase IA study to assess safety, tolerance, pharmacokinetics and efficacy of oral dosing icotinib hydrochloride tablets in various cancer patients,mainly in NSCLC.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 May 2012

At a glance

  • Drugs Icotinib (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Actual end date changed from May 2009 to 31 Dec 2009 as reported by Chinese Clinical Trial Register.
    • 21 May 2012 Actual initiation date changed from Dec 2007 to Nov 2007 as reported by Chinese Clinical Trial Register.
    • 21 May 2012 Trial phase changed from I to I/II as reported by Chinese Clinical Trial Register.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top